Blocking Myc to treat cancer : reflecting on two decades of Omomyc
Massó Vallés, Daniel (Peptomyc S.L.)
Soucek, Laura (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)

Date:	2020
Abstract:	First designed and published in 1998 as a laboratory tool to study Myc perturbation, Omomyc has come a long way in the past 22 years. This dominant negative has contributed to our understanding of Myc biology when expressed, first, in normal and cancer cells, and later in genetically-engineered mice, and has shown remarkable anti-cancer properties in a wide range of tumor types. The recently described therapeutic effect of purified Omomyc mini-protein-following the surprising discovery of its cell-penetrating capacity-constitutes a paradigm shift. Now, much more than a proof of concept, the most characterized Myc inhibitor to date is advancing in its drug development pipeline, pushing Myc inhibition into the clinic.
Grants:	European Commission 872212 Ministerio de Economía y Competitividad PI16-01224 European Commission 617473
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Omomyc ; Myc ; Cancer ; Myc inhibition ; Mouse models ; Peptides ; Anticancer drugs ; New therapeutics
Published in:	Cells, Vol. 9, Issue 4 (April 2020) , art. 883, ISSN 2073-4409

DOI: 10.3390/cells9040883
PMID: 32260326

19 p, 1.3 MB

The record appears in these collections:
Articles > Research articles
Articles > Published articles